Talk:Olanzapine

initial draft. This will contain a myriad of information and will be formatted later :) --Corticosteroid (talk) 22:58, 20 October 2017 (CEST)

Structure of olanzapine.

A five milligram tablet of olanzapine manufactured by Apotex. This tablet is designed to dissolve in the mouth and be absorbed through the blood vessels inside of the mouth.

Olanzapine, first branded as Zyprexa, is a widely-used antipsychotic substance of the thienobenzodiazepine chemical class. It produces sedating and neuroleptic effects when administered. Olanzapine can be given by mouth and can also be injected into a muscle. Olanzapine might be useful as a trip aborter, especially for stimulants, as it blocks the action of dopamine. ^{[citation needed]}

Chemistry

Olanzapine is a thienobenzodiazepine. It includes a piperazine moiety at R₄.

Pharmacology

Olanzapine is known to cause weight gain and induce diabetes mellitus type 2 more frequently than other antipsychotics. However, it is less likely to produce tardive dyskinesia or an extrapyramidal reaction. It appears to be an effective treatment for schizophrenia.^[1]

Subjective effects

Physical effects

- Hunger - This often happens over a course of treatment and not with one use.
- Sedation - This effect is more often uncomfortably tiring than relaxing.
- Salivation
- Muscle relaxation
- Motor control loss
- Dizziness
- Perception of bodily heaviness
- Headaches
- Extrapyramidal symptoms

Cognitive effects

- Anxiety suppression - This is mediated by olanzapine's antidopaminergic, antiadrenergic, and serotonergic action rather than GABA-related activity.
- Emotionality suppression - Olanzapine dulls and suppresses emotions.
- Focus suppression or enhancement - This often depends on the mental state of the individual.
- Decreased libido
- Sleepiness
- Cognitive euphoria - This effect is extremely rare. Olanzapine is often a dulling, "boring" pharmaceutical.
- Cognitive dysphoria - This often includes a sense of boredom or depression accompanied by uncomfortable sedation.

not the crème de là crème

(doses:

Light: 2.5 mg

Medium: 5 to 7.5 mg

Heavy: 10 mg

Strong: 10 mg +)

External links

References

↑ Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., ... & Kissling, W. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet, 382(9896), 951-962.

[1] Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., ... & Kissling, W. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet, 382(9896), 951-962.

[1]